Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04982991
Recruitment Status : Completed
First Posted : July 29, 2021
Last Update Posted : April 25, 2022
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objective:

To assess the pharmacokinetic parameters of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants.

Secondary Objective:

To assess the tolerability and safety of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants


Condition or disease Intervention/treatment Phase
Multiple Sclerosis Healthy Subjects Drug: RIPK1 inhibitor Phase 1

Detailed Description:

The duration of the study for a participant will be up to approximately 7 weeks and include:

  • Screening period: up to 4 weeks (Day -28 to Day -2).
  • Institutionalization period at each period of treatment: 4 days (Day -1 to Day 3, single SAR443820 administration on Day 1).
  • Wash-out period: at least 5 days between each dosing.
  • End-of-study visit: Period 3/ Day 6±1 day.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, 3-treatment Period, 1-sequence, Cross-over Study of the Pharmacokinetics, Safety and Tolerability After Single Ascending Oral Doses of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants.
Actual Study Start Date : August 5, 2021
Actual Primary Completion Date : October 11, 2021
Actual Study Completion Date : October 11, 2021


Arm Intervention/treatment
Experimental: SAR443820
Participants will receive a single sequence of 3 different doses of SAR443820 in a total of 3 treatment periods
Drug: RIPK1 inhibitor
Capsule Oral
Other Name: SAR443820




Primary Outcome Measures :
  1. Assessment of pharmacokinetic (PK) parameter: Cmax [ Time Frame: Up to day 3 ]
    Maximum plasma concentration

  2. Assessment of pharmacokinetic (PK) parameter: AUClast [ Time Frame: Up to day 3 ]
    Area under the plasma concentration versus time curve from time zero to the real time last

  3. Assessment of pharmacokinetic (PK) parameter: AUC [ Time Frame: Up to day 3 ]
    Area under the plasma concentration versus time curve


Secondary Outcome Measures :
  1. Assessment of adverse events (AEs) [ Time Frame: Up to day 21 ]
    Number of participants with Adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

East Asian (Chinese and Japanese) male and/or female participant must be 20 to 55 years of age inclusive, at the time of signing the informed consent.

Chinese or Japanese ethnicity, according to the following criteria:

Chinese; born in China or ethnic Chinese born outside of China, and a descendent of 4 ethnic Chinese grandparents who were all born in China.

Japanese; born in Japan or ethnic Japanese born outside of Japan, and a descendent of 4 ethnic Japanese grandparents who were all born in Japan.

Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG.

Body weight within 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, and body mass index (BMI) within the range 18.0 and 30.0 kg/m2, inclusive.

Exclusion Criteria:

Medical history of any seizure.

Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, any live attenuated vaccine given within 3 months or any non-live vaccine given within 2 weeks before inclusion, and any biologics (antibody or its derivatives) given within 4 months before inclusion.

Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test.

Current psychiatric disorder, suicidal ideation in the previous 6 months (as assessed by the Columbia-Suicide Severity Rating Scale [C-SSRS]), or a lifetime suicide attempt. A "yes" response to questions 4 or 5 on the Suicidal Ideation section, or a score of 4 or 5 on the Intensity of Ideation section of the baseline/screening version of the C-SSRS at screening, or on the Since Last Visit version of the C-SSRS at baseline.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04982991


Locations
Layout table for location information
United Kingdom
Investigational Site Number :8260001
Harrow, London, City Of, United Kingdom, HA1 3UJ
Sponsors and Collaborators
Sanofi
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT04982991    
Other Study ID Numbers: PKM17247
2021-001076-42 ( EudraCT Number )
U1111-1264-3008 ( Registry Identifier: ICTRP )
First Posted: July 29, 2021    Key Record Dates
Last Update Posted: April 25, 2022
Last Verified: April 8, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases